SynthesisBMC health services research2026
Systematic review of cost-effectiveness of Chinese PD-1/PD-L1 inhibitors as first-line treatment for hepatocellular carcinoma.
Yibing Hou et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.